PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 28, 2026Trends in cancer0 citationsOpen Access

ALPK1 agonists ignite innate immunity in anticancer therapy

View Full Paper
SMShreya MahajanHBHarrison BazleySMSi Ming Man

Key Points

  • The study aims to explore the effects of the synthetic agonist UDSP-Hep on innate immunity and antitumor activity.
  • Comparison of UDSP-Hep and ADP-Hep in enhancing antitumor activity
  • Evaluation of proinflammatory effects in the tumor microenvironment
  • Analysis of immune responses driven by ALPK1 agonists
  • UDSP-Hep shows greater antitumor activity than ADP-Hep.
  • UDSP-Hep shifts the tumor microenvironment to a more proinflammatory state.
  • Enhanced immune activation observed with UDSP-Hep compared to traditional agonists.

Abstract

Abstract A recent study published in Nature by Tian et al. identifies UDSP-Hep as a synthetic agonist of the innate immune receptor Alpha-protein kinase 1 (ALPK1) that induces enhanced antitumor activity compared with the canonical ALPK1 agonist ADP-Hep and Toll-like receptor or stimulator of interferon genes agonists. UDSP-Hep drives the tumor microenvironment toward a proinflammatory, antitumor state.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mahajan et al. (2026) studied this question.

synapsesocial.com/papers/69a286eb0a974eb0d3c023abhttps://doi.org/10.1016/j.trecan.2026.01.013
Ask AI
Helpful
Bookmark
Share
View Full Paper